1.0Leitat Technological Centerhttps://leitat.org/en/Dissemination Managerhttps://leitat.org/en/blog/author/editor-wp/rich600338<blockquote class="wp-embedded-content" data-secret="wqZ6OUcDjf"><a href="https://leitat.org/en/blog/nextom/">NEXTOM</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://leitat.org/en/blog/nextom/embed/#?secret=wqZ6OUcDjf" width="600" height="338" title="“NEXTOM” — Leitat Technological Center" data-secret="wqZ6OUcDjf" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script> /*! This file is auto-generated */ !function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document); //# sourceURL=https://leitat.org/wp-includes/js/wp-embed.min.js </script> https://leitat.org/wp-content/uploads/2025/12/Nextom-final.png19201080Development of Next-Generation ADCs (Antibody-Drug Conjugates) for the Treatment of Invasive Tumours Abstract: The NEXTOM project aims to develop innovative antibody-drug conjugates (ADCs) targeting components of the tumour microenvironment (such as FAP, Endoglin and Endo180), to treat invasive solid tumours with greater efficacy and lower toxicity. The initiative includes the selection of therapeutic candidates, their […]